FDA Calendar

PDUFA dates and FDA Panel Review dates are very important because they are make or break events for biostocks when the decisions are announced. Also, usually biostocks experience a run-up going into the scheduled decision/review dates. So having prior knowledge of the catalysts goes a long way toward maximizing profit or minimizing loss while trading volatile biotech stocks.
Listed below are large cap, mid cap and small cap stocks with pending regulatory catalysts.

Get in-depth analysis and insight on investing in the high-stakes biotech and pharma sectors. Check out our premium biotech research product and our biotech home page.
Company Name
Mylan N.V.
MYL-1402O (BLA)
FDA decision on MYL-1402O, a proposed biosimilar to Avastin
Urovant Sciences Ltd.
Vibegron (NDA)
FDA decision on Vibegron for the treatment of overactive bladder
AstraZeneca PLC
Roxadustat (NDA)
FDA decision on Roxadustat for the treatment of anemia of chronic kidney disease (CKD), in both non-dialysis-dependent and dialysis-dependent patients
Myovant Sciences Ltd
Relugolix (NDA)
FDA decision on once-daily, oral Relugolix for the treatment of men with advanced prostate cancer
FibroGen Inc.
Roxadustat (NDA)
FDA decision on Roxadustat for the treatment of anemia of chronic kidney disease (CKD), in both non-dialysis-dependent and dialysis-dependent patients
Amgen Inc.
ABP 798 (BLA)
FDA decision on ABP 798 (biosimilar rituximab) for Non-Hodgkin's lymphoma and Rheumatoid arthritis
MacroGenics Inc.
Margetuximab (BLA)
FDA decision on Margetuximab for the treatment of patients with metastatic HER2-positive breast cancer in combination with chemotherapy
Alnylam Pharmaceuticals Inc.
Lumasiran (NDA)
FDA decision on Lumasiran for the treatment of primary hyperoxaluria type 1 (PH1)
Biocryst Pharmaceuticals Inc
Berotralstat (BCX7353) (NDA)
FDA decision on berotralstat for prevention of hereditary angioedema (HAE) attacks
Y-mAbs Therapeutics, Inc.
Danyelza (BLA)
FDA decision on Danyelza for the treatment of patients with relapsed/refractory high-risk neuroblastoma
Setmelanotide (NDA)
FDA decision on Setmelanotide for pro-opiomelanocortin deficiency obesity and leptin receptor deficiency obesity
Revance Therapeutics, Inc.
FDA decision on DAXI in the treatment of moderate to severe glabellar (frown) lines
Liquidia Technologies Inc.
LIQ861 (NDA)
FDA decision on LIQ861 for the treatment of pulmonary arterial hypertension
Roche Holding AG
Nnew formulation of Xofluza (NDA)
FDA decision on Xofluza for the treatment of acute uncomplicated influenza in otherwise healthy children aged one to less than 12 years of age who have been symptomatic for no more than 48 hours
Roche Holding AG
New formulation of Xofluza as one-dose granules for oral suspension (NDA)
FDA decision on new formulation of Xofluza treat the flu (influenza) in people 12 years of age and older

ALSO READ - COVID-19 Drugs In Development Calendar which lists Companies that are in Race to find a Treatment or Vaccine for the Novel Coronavirus.

Buy this Content

stockmarkets jan22 02jul20 What's moving these stocks in the pre-market today?
pfizer july02 Today's Daily Dose brings you news about Pfizer/BioNTech's COVID-19 vaccine trial results; Blueprint's submission of Pralsetinib NDA; reverse merger of MedAvail with MYOS; Liminal BioSciences' efforts to fight the ongoing pandemic and upsized public offering of AdaptHealth.
akero july01 Today's Daily Dose brings you news about promising histological data from Akero's phase II NASH study; positive results of Inovio's phase I clinical trial of COVID-19 vaccine candidate INO-4800; Zynerba's Fragile X Syndrome trial results; Chiasma's stock offering; update on Alterity's phase I Multiple System Atrophy trial and disappointing results of Oncocyte's DetermaDx liquid biopsy test.
Read More
Wednesday, the United States hit a dismal record high of more than 50,000 coronavirus cases in a day. With 50049 new cases reporting in the last 24 hours, the total number of people who contacted the disease in the U.S. increased to 26,86,587, as per Johns Hopkins University's latest update on Thursday. This is a big spike from the previous worst daily number of new cases - 44726 - reported on
The U.S. Department of Health and Human Services or HHS said it has secured most of the supply of COVID-19 drug remdesivir through September. The deal would allow American hospitals to purchase the antiviral drug in allocated amounts amid the spike in confirmed cases each day. HHS Secretary Alex Azar said, "President Trump has struck an amazing deal to ensure Americans have access to the first..."
Cresco Labs Inc., a multi-state cannabis operator, said it has closed an agreement to sell and lease back its marijuana facility in Fall River, Massachusetts to Innovative Industrial Properties, Inc. or IIP. This is Cresco's fifth sale-and-leaseback agreement with IIP, a real estate company focused...
Read More